NVCR Stock Overview
An oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
NovoCure Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.08 |
| 52 Week High | US$34.13 |
| 52 Week Low | US$11.70 |
| Beta | 0.76 |
| 1 Month Change | 50.10% |
| 3 Month Change | 102.01% |
| 1 Year Change | 101.47% |
| 3 Year Change | -62.45% |
| 5 Year Change | -60.48% |
| Change since IPO | 64.55% |
Recent News & Updates
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump
Dec 03
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
Dec 02Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report
Nov 01Recent updates
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump
Dec 03Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
Dec 02Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report
Nov 01Is NovoCure (NASDAQ:NVCR) A Risky Investment?
Oct 17NovoCure: There Is Still More Upside
Oct 16NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
Oct 09Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects
Sep 12NovoCure Limited: A Post Q2 Analysis
Jul 26NovoCure Limited Q1 Earnings: Core Business Accelerating
May 03NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03NovoCure: Stay Cautious Amid Positive Signs
Jan 19Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Nov 16Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?
Aug 13Is NovoCure (NASDAQ:NVCR) A Risky Investment?
May 15A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)
Apr 24Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching
Feb 10Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Jan 16Shareholder Returns
| NVCR | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -1.3% | 0.8% | 0.6% |
| 1Y | 101.5% | 10.0% | 23.7% |
Return vs Industry: NVCR exceeded the US Medical Equipment industry which returned 10% over the past year.
Return vs Market: NVCR exceeded the US Market which returned 23.7% over the past year.
Price Volatility
| NVCR volatility | |
|---|---|
| NVCR Average Weekly Movement | 16.9% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NVCR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NVCR's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,453 | Asaf Danziger | www.novocure.com |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
NovoCure Limited Fundamentals Summary
| NVCR fundamental statistics | |
|---|---|
| Market cap | US$3.32b |
| Earnings (TTM) | -US$149.78m |
| Revenue (TTM) | US$577.74m |
5.6x
P/S Ratio-21.7x
P/E RatioIs NVCR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVCR income statement (TTM) | |
|---|---|
| Revenue | US$577.74m |
| Cost of Revenue | US$135.47m |
| Gross Profit | US$442.26m |
| Other Expenses | US$592.05m |
| Earnings | -US$149.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.38 |
| Gross Margin | 76.55% |
| Net Profit Margin | -25.93% |
| Debt/Equity Ratio | 181.4% |
How did NVCR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 00:16 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NovoCure Limited is covered by 15 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Difei Yang | Aegis Capital Corporation |
| Gregory Gilbert | Deutsche Bank |
| Vijay Kumar | Evercore ISI |